Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC

Abstract Background and aims Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance. The aim of this study was to identify the key lncRNA involved in the regulation of th...

Full description

Bibliographic Details
Main Authors: Yau-Tuen Chan, Junyu Wu, Yuanjun Lu, Qiucheng Li, Zixin Feng, Lin Xu, Hongchao Yuan, Tingyuan Xing, Cheng Zhang, Hor-Yue Tan, Yibin Feng, Ning Wang
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Molecular Cancer
Subjects:
CRISPR/Cas9 screens
LINC01056
Sorafenib
Hepatocellular carcinoma
Fatty acid oxidation
PPARα
Online Access:https://doi.org/10.1186/s12943-024-01988-y

Internet

https://doi.org/10.1186/s12943-024-01988-y

Similar Items